Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
Condition(s):Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non Hodgkin LymphomaLast Updated:June 8, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Non Hodgkin LymphomaLast Updated:June 8, 2022Recruiting
Condition(s):Hematologic MalignancyLast Updated:April 19, 2023Recruiting
Condition(s):B Cell LymphomaLast Updated:July 19, 2023Completed
Condition(s):Hodgkin Lymphoma, Adult; T Cell LymphomaLast Updated:December 4, 2020Unknown status
Condition(s):Diffuse Large B Cell LymphomaLast Updated:August 28, 2023Recruiting
Condition(s):Primary CNS LymphomaLast Updated:June 22, 2023Active, not recruiting
Condition(s):Acute Lymphoblastic Leukemia(ALL)Last Updated:October 1, 2020Unknown status
Condition(s):B-ALLLast Updated:March 11, 2021Unknown status
Condition(s):Lymphoma and Acute Lymphoblastic LeukemiaLast Updated:December 22, 2021Recruiting
Condition(s):DIPG Brain Tumor; Diffuse Intrinsic Pontine GliomaLast Updated:January 24, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.